Publications
Text queries can be conducted by Author, Title, or Keyword.
Neuroimaging as endpoints in clinical trials: Are we there yet? Perspective from the first provence workshop
Source: Molecular Psychiatry 2011 May;16:1064-1066.
Author: M Valenzuela, D Bartre´s-Faz, F Beg, A Fornito, E Merlo-Pich, U Mu¨ ller, D O¨ ngu¨ r, AW Toga and M Yu¨cel
Abstract:
Neuroimaging can now reveal an extraordinary amount of information about the structural, functional and biochemical characteristics of the human brain. Further understanding the biological processes underlying brain dysfunction, and how these adapt to treatment, is clearly of significance to researchers involved in medical trials. But how clinically meaningful is this information? A critical evaluation from conceptual and empirical perspectives was the goal of the first 'Neuroimaging as Endpoints in Clinical Trials’ provence workshop, run from 2 June to 5 June 2010 in the charming village of Sernhac, France. Several thought-provoking, interlinked and recurring themes emerged and are enumerated here to further advance a fast developing field.
Source: Molecular Psychiatry 2011 May;16:1064-1066.
Author: M Valenzuela, D Bartre´s-Faz, F Beg, A Fornito, E Merlo-Pich, U Mu¨ ller, D O¨ ngu¨ r, AW Toga and M Yu¨cel
Abstract:
Neuroimaging can now reveal an extraordinary amount of information about the structural, functional and biochemical characteristics of the human brain. Further understanding the biological processes underlying brain dysfunction, and how these adapt to treatment, is clearly of significance to researchers involved in medical trials. But how clinically meaningful is this information? A critical evaluation from conceptual and empirical perspectives was the goal of the first 'Neuroimaging as Endpoints in Clinical Trials’ provence workshop, run from 2 June to 5 June 2010 in the charming village of Sernhac, France. Several thought-provoking, interlinked and recurring themes emerged and are enumerated here to further advance a fast developing field.